Compare MCB & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | XERS |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | 2021 |
| Metric | MCB | XERS |
|---|---|---|
| Price | $98.01 | $8.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $98.67 | $10.83 |
| AVG Volume (30 Days) | 133.7K | ★ 2.4M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | 11.64 | ★ 100.00 |
| EPS | ★ 2.92 | 0.01 |
| Revenue | $11,053,000.00 | ★ $49,590,000.00 |
| Revenue This Year | $37.22 | $34.37 |
| Revenue Next Year | $14.75 | $22.86 |
| P/E Ratio | ★ $32.89 | $867.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $64.66 | $4.87 |
| 52 Week High | $102.04 | $10.08 |
| Indicator | MCB | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 76.13 |
| Support Level | $86.38 | $6.86 |
| Resistance Level | N/A | $10.08 |
| Average True Range (ATR) | 2.53 | 0.32 |
| MACD | -0.26 | 0.11 |
| Stochastic Oscillator | 55.86 | 77.31 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.